The stock of Sarepta Therapeutics Inc (SRPT) has gone down by -1.07% for the week, with a 2.01% rise in the past month and a 4.41% rise in the past quarter. The volatility ratio for the week is 2.28%, and the volatility levels for the past 30 days are 2.50% for SRPT. The simple moving average for the past 20 days is -1.43% for SRPT’s stock, with a 12.10% simple moving average for the past 200 days.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
Additionally, the 36-month beta value for SRPT is 0.95. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SRPT is 88.26M and currently, short sellers hold a 5.21% ratio of that float. The average trading volume of SRPT on April 12, 2024 was 913.31K shares.
SRPT) stock’s latest price update
Sarepta Therapeutics Inc (NASDAQ: SRPT)’s stock price has plunge by -1.47relation to previous closing price of 126.31. Nevertheless, the company has seen a -1.07% plunge in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-06 that Amgen’s lineup and pipeline should help its financial results and keep its dividend intact. While lesser known, Sarepta is proving itself to be a highly innovative biotech company.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with BMO Capital Markets repeating the rating for SRPT by listing it as a “Outperform.” The predicted price for SRPT in the upcoming period, according to BMO Capital Markets is $170 based on the research report published on January 31, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $113. The rating they have provided for SRPT stocks is “Buy” according to the report published on December 13th, 2023.
Deutsche Bank gave a rating of “Buy” to SRPT, setting the target price at $109 in the report published on December 12th of the previous year.
SRPT Trading at -1.91% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.17% of loss for the given period.
Volatility was left at 2.50%, however, over the last 30 days, the volatility rate increased by 2.28%, as shares surge +2.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.50% upper at present.
During the last 5 trading sessions, SRPT fell by -1.07%, which changed the moving average for the period of 200-days by +14.93% in comparison to the 20-day moving average, which settled at $126.38. In addition, Sarepta Therapeutics Inc saw 29.06% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Boor Kathryn Jean, who sale 761 shares at the price of $122.93 back on Mar 11 ’24. After this action, Boor Kathryn Jean now owns 7,516 shares of Sarepta Therapeutics Inc, valued at $93,550 using the latest closing price.
Wigzell Hans Lennart Rudolf, the Director of Sarepta Therapeutics Inc, sale 15,000 shares at $123.25 during a trade that took place back on Mar 08 ’24, which means that Wigzell Hans Lennart Rudolf is holding 22,840 shares at $1,848,795 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.88 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at -0.43. The total capital return value is set at -0.1. Equity return is now at value -86.15, with -16.77 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4.
Currently, EBITDA for the company is -267.82 million with net debt to EBITDA at -4.3. When we switch over and look at the enterprise to sales, we see a ratio of 10.17. The receivables turnover for the company is 2.83for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.95.
Conclusion
In conclusion, Sarepta Therapeutics Inc (SRPT) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
